Rubel Chakravarty
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Rubel Chakravarty has a total of 132 co-authors. Here are the top co-authors by number of shared publications:
Sudipta Chakraborty
Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Trombay, Mumbai, India
35 shared publicationsAshutosh Dash
Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Trombay, India
20 shared publications- Ashutosh Dash
Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Trombay, Mumbai 400 085, India
20 shared publications Sanchita Ghosh
17 shared publicationsSourav Patra
16 shared publications- Sudipta Chakraborty
Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Trombay, India
15 shared publications
Latest Publications
- 2 September 2026
- Published by Springer Nature
- p. 143-149
Radioisotopes for Healthcare
- Open Access
- 5 June 2026
- Published by Royal Society of Chemistry (RSC) in Nanoscale Advances
- Vol. 8 (14) , 3970-3974
Closing the loop in nanotheranostics: from 124 I separation to intrinsically radiolabeled platinum nanoparticles for potential PET/CT-guided photothermal therapy
From radioisotope production to therapy, high-purity 124 I is seamlessly integrated into platinum nanotheranostics, enabling quantitative PET imaging and effective photothermal therapy in a unified theranostic strategy.
- 5 June 2026
- Published by Royal Society of Chemistry (RSC) in Nanoscale Advances
- Vol. 8 (14) , 3970-3974
Open AccessClosing the loop in nanotheranostics: from 124 I separation to intrinsically radiolabeled platinum nanoparticles for potential PET/CT-guided photothermal therapy
From radioisotope production to therapy, high-purity 124 I is seamlessly integrated into platinum nanotheranostics, enabling quantitative PET imaging and effective photothermal therapy in a unified theranostic strategy.
- Open Access
- 14 April 2026
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 16 (22) , 20241-20256
Rhenium-186-labeled ortho -hydroxythiobenzhydrazide: a potential theranostic agent for use in metastatic breast cancer
Ortho -hydroxythiobenzhydrazide was radiolabelled using [ 186 Re]ReO 4 − to yield the [ 186 Re]Re-(htbh) 2 complex with high radiochemical purity, stability and targeting potential for metastatic breast cancer.
- 14 April 2026
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 16 (22) , 20241-20256
Open AccessRhenium-186-labeled ortho -hydroxythiobenzhydrazide: a potential theranostic agent for use in metastatic breast cancer
Ortho -hydroxythiobenzhydrazide was radiolabelled using [ 186 Re]ReO 4 − to yield the [ 186 Re]Re-(htbh) 2 complex with high radiochemical purity, stability and targeting potential for metastatic breast cancer.
- 11 April 2026
- Published by Springer Nature in Journal of Radioanalytical and Nuclear Chemistry
- Vol. 335 (5) , 3419-3445
Materials science in reactor production of medical radioisotopes: target design, irradiation engineering, and radiochemical processing
- 11 April 2026
- Published by Springer Nature in Journal of Radioanalytical and Nuclear Chemistry
- Vol. 335 (5) , 3419-3445
Materials science in reactor production of medical radioisotopes: target design, irradiation engineering, and radiochemical processing
- Open Access
- 1 April 2026
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 16 (20) , 18187-18198
Porous hydroxyapatite microparticles loaded with 169 Er for treatment of chronic inflammatory disease of small joints: harnessing mechanochemistry for synthesis of an advanced biomaterial
In the present study, nanoporous hydroxyapatite microparticles (HA MPs) were synthesized using a d (+)-glucose template mediated solid state mechanochemical approach.
- 1 April 2026
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 16 (20) , 18187-18198
Open AccessPorous hydroxyapatite microparticles loaded with 169 Er for treatment of chronic inflammatory disease of small joints: harnessing mechanochemistry for synthesis of an advanced biomaterial
In the present study, nanoporous hydroxyapatite microparticles (HA MPs) were synthesized using a d (+)-glucose template mediated solid state mechanochemical approach.
- Open Access
- 1 January 2026
- Published by Royal Society of Chemistry (RSC) in RSC Advances
Engineering intrinsically radiolabeled nanoparticles for imaging and therapy: a decade of design strategies and insights
Intrinsic radiolabeling embeds radionuclides directly into nanoparticle frameworks, enabling exceptional radiochemical stability, multimodal imaging, radionuclide therapy, and advanced nanotheranostic platforms through rational design.
- 1 January 2026
- Published by Royal Society of Chemistry (RSC) in RSC Advances
Open AccessEngineering intrinsically radiolabeled nanoparticles for imaging and therapy: a decade of design strategies and insights
Intrinsic radiolabeling embeds radionuclides directly into nanoparticle frameworks, enabling exceptional radiochemical stability, multimodal imaging, radionuclide therapy, and advanced nanotheranostic platforms through rational design.
- 17 July 2025
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 17 (30) , 42767-42780
Bioinspired Synthesis of Intrinsically Radiolabeled Dy2O3 Nanoparticles as an In Vivo Generator of 166Dy/166Ho: A Smart Choice for Theranostics Engineering
Functionalized inorganic nanoparticles (NPs) intrinsically radiolabeled with theranostic radiometals hold the potential to revolutionize cancer management. The appropriate choice of the radiometal used in the nanoplatform would not only aid in the diagnosis and staging of the disease but also facilitate them becoming an integral part of the therapeutic regimen, either as an independent treatment or in combination with other conventional modalities. Furthermore, due to the inherent characteristics of the NPs, such systems can demonstrate potential in multimodality imaging to offer improved diagnostic and therapeutic monitoring abilities for personalized treatment. In this study, intrinsically radiolabeled dysprosium oxide NPs were synthesized in a bioinspired manner for use as an efficient 166Dy/166Ho in vivo generator. The synthesized NPs (average size of 12.5 ± 2.4 nm) were extensively characterized by various instrumental techniques, including DLS, HRTEM, XRD, XPS, XANES, EXAFS, Raman spectroscopy, TGA, etc. Besides single-photon emission computed tomography (SPECT) imaging due to the nuclear decay characteristics of 166Dy/166Ho, the synthesized NPs demonstrated potential for use as contrast agents for magnetic resonance imaging (MRI) and computed tomography (CT) imaging, thereby combining three different imaging modalities in the same nanoplatform. In silico studies predicted the radiochemical stability and suitability of the intrinsically radiolabeled NPs for use as in vivo generator, which was further corroborated by SPECT imaging and biodistribution studies. Additionally, footpad administration of the intrinsically radiolabeled NPs led to clear visualization of the popliteal lymph node, highlighting their suitability for noninvasive sentinel lymph node mapping and for potential radiotherapy-based ablation of metastatic lymph nodes. Overall, this unique nanoplatform demonstrates promise for simultaneous diagnosis and therapy monitoring by multimodality (SPECT/MRI/CT) imaging along with precise cancer treatment.
- 17 July 2025
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 17 (30) , 42767-42780
Bioinspired Synthesis of Intrinsically Radiolabeled Dy2O3 Nanoparticles as an In Vivo Generator of 166Dy/166Ho: A Smart Choice for Theranostics Engineering
Functionalized inorganic nanoparticles (NPs) intrinsically radiolabeled with theranostic radiometals hold the potential to revolutionize cancer management. The appropriate choice of the radiometal used in the nanoplatform would not only aid in the diagnosis and staging of the disease but also facilitate them becoming an integral part of the therapeutic regimen, either as an independent treatment or in combination with other conventional modalities. Furthermore, due to the inherent characteristics of the NPs, such systems can demonstrate potential in multimodality imaging to offer improved diagnostic and therapeutic monitoring abilities for personalized treatment. In this study, intrinsically radiolabeled dysprosium oxide NPs were synthesized in a bioinspired manner for use as an efficient 166Dy/166Ho in vivo generator. The synthesized NPs (average size of 12.5 ± 2.4 nm) were extensively characterized by various instrumental techniques, including DLS, HRTEM, XRD, XPS, XANES, EXAFS, Raman spectroscopy, TGA, etc. Besides single-photon emission computed tomography (SPECT) imaging due to the nuclear decay characteristics of 166Dy/166Ho, the synthesized NPs demonstrated potential for use as contrast agents for magnetic resonance imaging (MRI) and computed tomography (CT) imaging, thereby combining three different imaging modalities in the same nanoplatform. In silico studies predicted the radiochemical stability and suitability of the intrinsically radiolabeled NPs for use as in vivo generator, which was further corroborated by SPECT imaging and biodistribution studies. Additionally, footpad administration of the intrinsically radiolabeled NPs led to clear visualization of the popliteal lymph node, highlighting their suitability for noninvasive sentinel lymph node mapping and for potential radiotherapy-based ablation of metastatic lymph nodes. Overall, this unique nanoplatform demonstrates promise for simultaneous diagnosis and therapy monitoring by multimodality (SPECT/MRI/CT) imaging along with precise cancer treatment.
- Open Access
- 19 June 2025
- Published by Wiley in Small Science
- Vol. 5 (8)
Radiolabeled Nanogels: From Multimodality Imaging to Combination Therapy of Cancer
Advancements in nanotechnology over the past few decades have offered tremendous possibilities toward cancer theranostics. Radiolabeled nanogels (NGs) represent a promising nanoplatform in this direction, offering a multifunctional toolset for both imaging and therapeutic interventions. This review encapsulates the progressions and potential of radiolabeled NGs in the realm of cancer research. Firstly, multifunctional radiolabeled NGs serve as potent contrast agents for multimodality imaging, enabling precise visualization of tumor sites through various techniques such as positron emission tomography, single‐photon emission computed tomography, optical imaging and magnetic resonance imaging. Furthermore, by incorporating more than one therapeutic payload such as chemotherapeutic drugs, nucleic acids, and/or therapeutic radionuclides, they enable synergistic treatment modalities that address the heterogeneity of cancer cells and their microenvironment. This combination approach allows for enhanced therapeutic efficacy while minimizing systemic toxicity, addressing challenges associated with conventional cancer therapies. Furthermore, the radiolabeling of NGs provides a means for real‐time monitoring of therapeutic distribution and pharmacokinetics, offering valuable insights into treatment response and optimization. Overall, radiolabeled NGs represent a promising platform for the integration of multimodality imaging and combination therapy in the fight against cancer with increased efficacy, reduced toxicity, and improved patient outcomes.
- 19 June 2025
- Published by Wiley in Small Science
- Vol. 5 (8)
Open AccessRadiolabeled Nanogels: From Multimodality Imaging to Combination Therapy of Cancer
Advancements in nanotechnology over the past few decades have offered tremendous possibilities toward cancer theranostics. Radiolabeled nanogels (NGs) represent a promising nanoplatform in this direction, offering a multifunctional toolset for both imaging and therapeutic interventions. This review encapsulates the progressions and potential of radiolabeled NGs in the realm of cancer research. Firstly, multifunctional radiolabeled NGs serve as potent contrast agents for multimodality imaging, enabling precise visualization of tumor sites through various techniques such as positron emission tomography, single‐photon emission computed tomography, optical imaging and magnetic resonance imaging. Furthermore, by incorporating more than one therapeutic payload such as chemotherapeutic drugs, nucleic acids, and/or therapeutic radionuclides, they enable synergistic treatment modalities that address the heterogeneity of cancer cells and their microenvironment. This combination approach allows for enhanced therapeutic efficacy while minimizing systemic toxicity, addressing challenges associated with conventional cancer therapies. Furthermore, the radiolabeling of NGs provides a means for real‐time monitoring of therapeutic distribution and pharmacokinetics, offering valuable insights into treatment response and optimization. Overall, radiolabeled NGs represent a promising platform for the integration of multimodality imaging and combination therapy in the fight against cancer with increased efficacy, reduced toxicity, and improved patient outcomes.